Next generation sequencing NGS News and Research

RSS

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

EKF Diagnostics subsidiary, Selah Genomics, has announced a major, four-way collaboration with Greenville Health System, DecisionQ Corporation, and BD.

From EKF Diagnostics 26 Feb 2015

Agena releases MassARRAY 24-Well System for mass spectrometry-based genetic testing

Agena Bioscience today released the MassARRAY 24-Well System for mass spectrometry-based genetic analysis, adding to its existing MassARRAY portfolio. The new 24-well format is tailored to smaller clinical testing laboratories requiring modest sample throughput, reduced initial hardware costs, and reduced time to result.

24 Feb 2015

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2014.

24 Feb 2015

MRIGlobal awarded contract to develop Sample-to-Sequence system for diagnosis of infectious diseases

MRIGlobal today announced that it has been awarded a $14.8 million contract to develop an end-to-end next generation sequencing system for clinical diagnosis of infectious diseases.

23 Feb 2015

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC).

20 Feb 2015

Sigma-Aldrich announces release of Next-Gen Sequencing Oligos

Sigma-Aldrich Corporation today announced that Sigma Life Science, its innovative biological products and services business, released Next-Gen Sequencing Oligos, custom next-generation sequencing adapters that improve target sequence assembly.

18 Feb 2015

Caris Life Sciences announces record-setting revenue for 2014

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced select year-end financial and operational results for 2014, which include record-setting revenue and continued case volume growth for its panomic, comprehensive tumor profiling service, Caris Molecular Intelligence.

18 Feb 2015

Quest Diagnostics, Myriad Genetics reach agreement to end BRCA gene-patent litigation

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation.

From Quest Diagnostics 10 Feb 2015

Roche announces acquisition of Signature Diagnostics

Roche announced today the acquisition of Signature Diagnostics AG, a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are constructed from multicenter prospective clinical studies.

From Roche Sequencing and Life Science 10 Feb 2015

BGI study tracks accuracy of NIFTY prenatal test

BGI has published a study tracking the clinical performance of its whole genome sequencing-based non-invasive prenatal test (the NIFTY test) in nearly 147,000 pregnancies, the largest such study to date. The results showed high sensitivity and specificity and no significant difference between high-risk and low-risk pregnant women.

6 Feb 2015

New study examines the methylome of triple-negative breast cancer

The new study, published in Nature Communications, compares the breast cancer DNA 'methylome' with that of healthy individuals. The methylome provides a new picture of the genome and shows how it is epigenetically 'decorated' with methyl groups, a process known as DNA 'methylation'.

3 Feb 2015

AstraZeneca announces research collaborations to use genome-editing tool for drug discovery and development

AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas.

30 Jan 2015

NovellusDx presents data from studies on Precision Cancer Analysis platform at PMWC 2015

NovellusDx, the leading Precision Cancer Analysis company delivering actionable intelligence about the mutational hierarchies that drive each patient’s cancer progression, announced today that the company will highlight data from studies on its Precision Cancer Analysis platform, at the Personalized Medicine World Conference 2015 in Silicon Valley.

27 Jan 2015

BRCA1/2 analysis: an interview with Jurgi Camblong, CEO of Sophia Genetics

BRCA1 and BRCA2 genes are two of the most well studied genes in the cancer field. They are tumor suppressors - mutations in these genes can lead to breast and/or ovarian cancer. Predispositions can be detected in women before they develop cancer.

26 Jan 2015

New study characterizes genetic underpinnings of phyllodes tumors

A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of a rare type of breast tumor called phyllodes tumors, offering the first comprehensive analysis of the molecular alterations at work in these tumors.

16 Jan 2015

UH Case Medical Center, ABL partner to design and validate HIV drug resistance tests

University Hospitals Case Medical Center has signed an agreement with Advanced Biological Laboratories, an information technology and diagnostic company based in Luxembourg, to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS).

14 Jan 2015

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours.

14 Jan 2015

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Researchers from the Republic of Korea have found that epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations can occur concomitantly in a proportion of patients with non-small-cell lung cancer.

12 Jan 2015

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Features of the blast phase, such as blast cell morphology and accompanying cytogenetic changes, vary between chronic myeloid leukaemia patients who received tyrosine kinase inhibitor therapy and those treated in the pre-TKI era, research shows.

12 Jan 2015

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, and Human Longevity, Inc., the human health information technology and health care company, today announced that HLI will have access to PGDx's cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete.

12 Jan 2015

Next generation sequencing NGS News and Research

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

Agena releases MassARRAY 24-Well System for mass spectrometry-based genetic testing

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

MRIGlobal awarded contract to develop Sample-to-Sequence system for diagnosis of infectious diseases

Betaretrovirus may infect patients with primary biliary cirrhosis

Sigma-Aldrich announces release of Next-Gen Sequencing Oligos

Caris Life Sciences announces record-setting revenue for 2014

Quest Diagnostics, Myriad Genetics reach agreement to end BRCA gene-patent litigation

Roche announces acquisition of Signature Diagnostics

BGI study tracks accuracy of NIFTY prenatal test

New study examines the methylome of triple-negative breast cancer

AstraZeneca announces research collaborations to use genome-editing tool for drug discovery and development

NovellusDx presents data from studies on Precision Cancer Analysis platform at PMWC 2015

BRCA1/2 analysis: an interview with Jurgi Camblong, CEO of Sophia Genetics

New study characterizes genetic underpinnings of phyllodes tumors

UH Case Medical Center, ABL partner to design and validate HIV drug resistance tests

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

How to optimize sample preparation for NGS? eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News